0

Jose Lizardo Ramon Vera

Universidad Surcolombiana, Colombia

Title: Sclerosing treatment in keloid of the auricular pavilion: alternative treatment and casuistry presentation

Abstract

Background and objective: Keloid is a pathology of the human being which mainly affects the black race, it is common in the young population, especially the female sex, and it affects the auricle considerably; however, it is not the most affected region and it has a high capacity for recurrence, causing serious aesthetic and psychological sequelae.

Even though multiple therapeutic options have been proposed, there is no evidence of a treatment that has obtained an efficacy greater than 80% and that maintains result over time. For this reason, we present a study that proposes the relationship between sclerotherapy and the management of keloids of the auricle as an effective and novel outpatient strategy in the treatment of auricular keloids.

Methods. Case series study at the Plastic Surgery Center of the Neiva University Hospital, Huila (Colombia) between 2013 and 2019 on patients with auricular keloids treated by intralesional infiltration of sclerosant or combined therapy that consisted of surgical resection plus infiltration with sclerosant. We evaluated demographic and clinical data, history of previous frustrated procedures, number of keloids, and recurrence. The information on the characteristics of the patients and the keloids treated were entered into the Stata software®.

Results. We studied 24 patients with a total of 34 auricular keloids. In all of them we performed the procedure without inconvenience and with good tolerance; 88% of the keloids did not present recurrence after 3 years of follow-up.

Conclusions. In our experience, treatment with sclerosing therapy is a management alternative with favorable results for ear keloids, which can be used as monotherapy or as adjunctive therapy to surgical resection in patients with or without a history of previous frustrated medical management.

Biography

WILL BE UPDATED SOON.